# Third Military Medical University: locus coeruleus inhibition restores sleep in mice

- Published: 2026-11-14 23:03 UTC
- Section: Life & Health › Neurotechnology
- Tags: locus coeruleus, optogenetic inhibition, tau pathology, P301S mice, sleep architecture, recognition memory, Alzheimer's model, noradrenergic neurons
- URL: https://realtech.media/news/rt-7363c100c4ac6254cf2beaa5_third_military_medical/

**In mice with tau pathology, optogenetic inhibition of overactive locus coeruleus neurons reversed sleep disruption and the loss of recognition memory, the authors report.**

![Third Military Medical University: locus coeruleus inhibition restores sleep in mice](https://realtech.media/media/2026/11/89241d74fd514fec.webp)
*ad-hoc-news.de*

Researchers at the Third Military Medical University studied the cellular processes behind sleep disturbances in neurodegenerative disease, using Alzheimer's disease models, according to ad-hoc-news.de. In P301S mice and in cell-type-specific tau overexpression models, pathological tau selectively increased the excitability of noradrenergic neurons in the locus coeruleus [1]. This brainstem nuclear complex helps regulate wakefulness, attention and sleep.

## Overexcited neurons and disrupted sleep

The hyperexcitability was accompanied by marked changes in sleep architecture. In the animals, both REM sleep and slow-wave activity were measurably reduced, while sleep fragmentation and so-called microarousals increased [1]. The persistent hyperactivity was also followed by a clear impairment of recognition memory [1].

To test the causal link between neuronal dysfunction and cognitive deficits, the team used an optogenetic intervention. Targeted inhibition of tau-positive neurons in the locus coeruleus reversed the disturbed sleep patterns [1]. With sleep behavior normalized, the recognition memory deficits were also eliminated [1].

Specialists cited in the report conclude that early intervention restoring sleep homeostasis by calming overactive neuronal groups could open new routes for treating early disease stages. This is their interpretation; the experiments themselves were carried out in mice.

## Context: current Alzheimer's therapies

The report places the work against the background of disease-modifying antibodies. Lecanemab and donanemab have been available for about a year [1]. In approval trials, lecanemab slowed cognitive and functional decline by about 27 percent relative to placebo over 18 months. Donanemab slowed it by about 22 percent after 76 weeks in the whole study population and by about 35 percent in patients with low to medium tau pathology [1].

In Switzerland, donanemab has been approved since early 2026, but reimbursement by health insurers is still pending because the drug is not yet on the specialty list of the Federal Office of Public Health.

Existing drugs slow the course of the disease but neither stop nor cure it, so the scientific focus is shifting to the phase before first symptoms appear. The large prevention trials AHEAD 3-45, TRAILBLAZER-ALZ 3 and PrevenTRON are currently testing lecanemab, donanemab or trontinemab in asymptomatic stages [1]. The blood biomarker pTau217 is regarded as a promising tool for early detection, but the method is not yet suitable for population-wide screening.

## Sources

1. [ad-hoc-news.de](https://www.ad-hoc-news.de/wissenschaft/locus-coeruleus-optogenetische-hemmung-stellt-schlaf-und-gedaechtnis-wieder-her/70510657)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-7363c100c4ac6254cf2beaa5_third_military_medical/